Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $2.2 million.

  • Northwest Biotherapeutics' Cash & Equivalents rose 55.15% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 55.15%. This contributed to the annual value of $2.2 million for FY2024, which is 2.30% up from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' Cash & Equivalents is $2.2 million, which was up 2.30% from $2.1 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Cash & Equivalents registered a high of $15.2 million during FY2021, and its lowest value of $2.1 million during FY2023.
  • In the last 3 years, Northwest Biotherapeutics' Cash & Equivalents had a median value of $2.2 million in 2024 and averaged $3.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 2,583.60% in 2020, then crashed by 69.48% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Cash & Equivalents (Yearly) stood at $10.0 million in 2020, then skyrocketed by 51.95% to $15.2 million in 2021, then crashed by 54.08% to $7.0 million in 2022, then slumped by 69.48% to $2.1 million in 2023, then rose by 2.30% to $2.2 million in 2024.